What Menaderm Clio Treats: Main Uses and Benefits

This medication is generally used in situations involving certain distressing symptoms of inflammatory skin conditions (dermatoses), such as Eczema and specific types of Dermatitis, that have become complicated by microbial activity. The therapeutic domain for this combination class is generally considered relevant when supportive symptom management is appropriate due to this microbial complication. This application offers a supportive therapeutic benefit by managing inflammation alongside the microbial activity, which helps provide symptomatic relief. The medication is also relevant for managing symptoms associated with conditions like Psoriasis and Prurigo nodularis.

The medication is used for managing challenging manifestations of acute, severe symptoms that interfere with daily functioning, including intense itchiness (pruritus), significant inflammation, and persistent redness. This symptomatic approach is considered relevant when a potent anti-inflammatory effect and management of microbial activity is appropriate. The treatment assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

“This application offers a supportive therapeutic benefit by managing inflammation alongside the microbial activity, which helps provide symptomatic relief.”

Quick Fact: Symptomatic Support

Menaderm Clio (Betamethasone/Clioquinol) is strictly regulated for use, with specific rules governing eligible and contraindicated populations as defined by regulatory bodies.

Who Cannot Use This Medicine (Contraindications)

Use of Menaderm Clio is contraindicated and must be avoided for:

• Hypersensitivity: Individuals with a known allergy to the active ingredients (betamethasone, clioquinol), iodine, or any of the inactive components.
• Age Restrictions: Children under 2 years of age. Use is not recommended for children under 12 years.
• Skin Conditions: Patients with rosacea, acne vulgaris, perioral dermatitis, ulcers, or atrophic skin diseases.
• Infections: Skin lesions caused by primary viral infections (e.g., herpes, chickenpox), tuberculous processes, syphilitic processes, or primary fungal or bacterial infections.
• Location: Application in the eyes or on open wounds, perianal, or genital pruritus.

Populations with Use Restrictions

• Pregnancy and Lactation: Should not be used during pregnancy, particularly the first trimester, or during lactation, unless a physician determines the benefit outweighs the risk. Avoid use on large areas, prolonged periods, or with occlusive dressings in these states.
• Adolescents: Indicated for use in adults and adolescents older than 12 years with specific corticosteroid-responsive dermatoses complicated by infection.

Interactions with other medicines and products

When using Menaderm Clio, it is important to be aware of how the active ingredients may interact with other substances or influence medical tests. The product contains the antimicrobial agent clioquinol, which includes iodine in its chemical structure, and the corticosteroid beclometasone.

Interference with Laboratory Tests

Systemic absorption of clioquinol, though generally minimal with topical use, can be increased under certain conditions, such as application to large skin areas, prolonged treatment, or use under occlusive dressings. If absorbed, the iodine component of clioquinol may interfere with diagnostic tests.

• Thyroid Function Tests: The use of clioquinol may lead to alterations in thyroid function tests, specifically by artificially increasing levels of protein-bound iodine (PBI) in the blood. For this reason, it is necessary to inform your healthcare provider that you are using this product if you are scheduled for any thyroid function assessments.
• Ferric Chloride Test: Clioquinol may also potentially cause a false-positive result in the ferric chloride test, which is sometimes used to screen for certain metabolic conditions like phenylketonuria, if trace amounts are present in the urine.

Interactions with Other Medicines

No specific medicinal products or therapeutic drug classes are consistently listed in authoritative interaction sections as being prohibited or requiring mandatory dose adjustment due to a direct drug-drug interaction with Menaderm Clio. However, due to the potential for systemic absorption of the corticosteroid (beclometasone) and clioquinol, patients should inform their healthcare providers about all other medications, topical preparations, and supplements they are currently using. Absorption of topical corticosteroids is generally low but may be enhanced by occlusive use, potentially leading to systemic corticosteroid effects which could interact with treatments for diabetes or other systemic conditions.

Menaderm Clio is a topical combination that modulates inflammatory pathways via beclometasone dipropionate and inhibits microbial proliferation via clioquinol.

Beclometasone dipropionate, a corticosteroid, enters the target cell and binds to the glucocorticoid receptor. The activated complex translocates to the nucleus, where it induces the synthesis of specific proteins, primarily phospholipase A2 inhibitory proteins, collectively termed lipocortins. Lipocortins subsequently inhibit the activity of phospholipase A2, thereby preventing the release of arachidonic acid from cell membrane phospholipids. This block in the cascade reduces the synthesis of inflammatory mediators, including prostaglandins and leukotrienes. The resulting decrease in mediator concentration leads to modulation of local vasodilation, capillary permeability, and cellular infiltration.

Clioquinol, a halogenated hydroxyquinoline, interferes with the proliferation of susceptible bacteria and fungi. Its proposed mechanism involves the chelation of trace metals required as cofactors for microbial metabolic enzymes, thereby inhibiting their growth and function. The overall effect is dual pathway modulation and direct cell-level inhibition.

Menaderm Clio is strictly designated for topical application to the skin. The choice between the available forms—the cream (crema) or the ointment (pomada)—is determined by the lesion characteristics, with the cream typically used for moist or weeping areas and the ointment reserved for dry, scaly skin.

Administration and Dosing Regimen

The standard regimen involves applying a small quantity as a thin film, which must be gently rubbed in until absorbed. Treatment is typically initiated two or three times daily; however, this frequency should be reduced to once daily or less often immediately upon clinical improvement. The medication is intended for short-term use, with continuous treatment generally limited to a maximum of seven days to four weeks, depending on the site of application. If the condition shows no improvement after two to four weeks, the diagnosis and treatment protocol require a formal reassessment.

Special Procedural Constraints

Several procedural rules govern administration. Occlusive dressings or tight-fitting diapers must not be used over the treated area. Furthermore, the use of the product in the pediatric population is subject to explicit restrictions: it is not recommended for children under 2 years of age, and the total duration of treatment courses for older children should be strictly limited to a maximum of five days.

Research Evidence: Overview of Studies for Menaderm Clio

Evidence for Use in Inflammatory Dermatoses Complicated by Infection

Research explored the formulation that combines two active ingredients, which is relevant in research contexts involving conditions characterized by fluctuating or episodic manifestations and suspected microbial involvement. Short-term Randomized Controlled Trials (RCTs) have been used in research exploring short-term symptom changes in these conditions.

These trials examined whether the combination formulation was observed in studies examining symptom intensity or variability. Researchers monitored outcomes monitoring physiological strain or stress, such as the severity of redness (erythema) and infiltration. The studies also documented microbial outcomes related to the status of the suspected bacteria or fungi. Findings describe patterns observed in the studies, which contributes to understanding symptom patterns over defined time intervals.

Types of Clinical Outcomes Measured in Trials

Research on this combination formulation has focused on outcomes related to systemic or functional imbalance and the severity of physical symptoms. The outcomes monitored include changes measured during the study period related to physical discomfort and outcomes describing episodic or acute changes.

Studies monitored the assessment of objective clinical signs and studies examining patient-reported outcomes describing perceived discomfort, especially intense pruritus (itching). The evidence provides insight into short-term changes and studies contribute to the broader evidence landscape.

Research Gaps and Areas of Remaining Uncertainty

The evidence level for this specific dual-active formulation is broadly described as Moderate. The research landscape has several limitations, primarily because the majority of formal clinical trial evidence relates to periods of two to four weeks of use.

Long-term effects are not fully established as follow-up durations were limited to acute treatment periods. Data for certain patient groups, such as children and adolescents, remains insufficient. Furthermore, comparative evidence is lacking for direct, modern comparison against every alternative therapy. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References Summary of Product Characteristics (SmPC): Betnovate-C (Betamethasone Valerate/Clioquinol) - HPRA

Common questions about Menaderm Clio (FAQ)

Q: Can Menaderm Clio be used on the face?

A: Official product information advises caution regarding use on the face. The product is contraindicated (should not be used) for certain skin conditions commonly found on the face, such as rosacea, acne, and inflammation around the mouth (perioral dermatitis). If use on other facial areas is considered, regulatory information suggests the duration of treatment is limited. Contact with the eyes and the area around them must be strictly avoided.

Q: Does Menaderm Clio interact with any other medications?

A: Regulatory documents state that no specific medicinal products or therapeutic drug classes are listed as being prohibited or requiring mandatory dose adjustment due to a direct interaction with Menaderm Clio. However, regulatory warnings emphasize the importance of communicating all other medications, supplements, and topical preparations being used to the prescribing healthcare provider, as a general safety precaution.

Q: What happens if I use Menaderm Clio for longer than the recommended treatment period?

A: Official warnings state that prolonged use or application to large areas of skin can lead to increased systemic absorption of the potent corticosteroid component. This means the medicine is absorbed into the bloodstream, which may cause unwanted effects. These risks include the potential for adrenal gland disorders. Regulatory safety information indicates that treatment duration is limited to mitigate this risk.

Q: What should I do if I accidentally swallow Menaderm Clio?

A: Menaderm Clio is designated strictly for topical use on the skin. Due to the way this medicine is administered and absorbed, the possibility of serious systemic intoxication (poisoning affecting the whole body) from accidental ingestion is considered very low by regulatory bodies.

Q: Is Menaderm Clio available over the counter?

A: According to the official classification, Menaderm Clio is a prescription-only medicine. It is not available for purchase over the counter and requires authorization from a healthcare provider.

How to Store and Dispose of Menaderm Clio?

The official regulatory labeling indicates that Menaderm Clio does not require special storage conditions for conservation, meaning standard room temperature is acceptable. The product has a labeled shelf life of five years and must not be used past the expiration date on the packaging.

Storage Mandates

Disposal Instructions

To prevent environmental contamination, the medicine must not be discarded down the drains or into the household rubbish. Unused product and containers must be deposited at the pharmacy’s designated collection point for proper pharmaceutical waste management, as mandated by official regulations.